4.7 Review

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Journal

Publisher

MDPI
DOI: 10.3390/ijms221910594

Keywords

ocular therapeutics; age-related macular degeneration; gene therapy; cell therapy; bispecific antibodies; port delivery system

Ask authors/readers for more resources

Age-related macular degeneration (AMD) is a common cause of vision loss in the elderly population, and intravitreal injections are a popular treatment option. To address the challenges of short half-life and patient compliance with these injections, various technologies and therapies are being developed to reduce injection frequency and improve efficacy. In addition to the frequent IVT injections, molecular therapies such as cell therapy and gene therapy offer the potential for restoration of vision, with recent advancements in ocular gene therapy providing new hope in this direction.
Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available